A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms

NCT07629726 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematologic Neoplasms

Interventions

DRUG: KK2430

Sponsor

Kyowa Kirin Co., Ltd.